Makoto Wada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Makoto Wada has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Jun Asai
Department of Dermatology Kyoto Prefectural University of Medicine Graduate School of Medical Science Kyoto Japan
18 shared publications Norito Katoh
Department of Dermatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
16 shared publicationsHideya Takenaka
Department of Dermatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
10 shared publicationsMaiko Taura
Department of Dermatology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
4 shared publications- Norito Katoh
Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
4 shared publications - Norito Katoh
Kyoto Prefectural University of Medicine Graduate School of Medical Science
4 shared publications
Latest Publications
- 3 September 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (12) , E437-E438
Subcutaneous nodule showing loss of BAP1 in large plaque‐type blue nevus: Melanoma or not?
- 3 September 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (12) , E437-E438
Subcutaneous nodule showing loss of BAP1 in large plaque‐type blue nevus: Melanoma or not?
- 3 March 2020
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 47 (7) , 584-591
CD163‐positive macrophage infiltration predicts systemic involvement in sarcoidosis
Background: Sarcoidosis is a chronic and systemic inflammatory disease, in which patients present with noncaseating epithelioid granulomas. Cutaneous lesions of sarcoidosis develop in 9% to 35% of all sarcoidosis patients and comprise various clinical subtypes. It usually affects multiple organs and has a variable clinical course; this is called systemic sarcoidosis (SS). However, occasionally, it only affects the skin and is then called cutaneous sarcoidosis (CS). Recent observations suggest that serum levels of soluble CD163 correlate with immune cell activity in sarcoidosis patients; however, the contribution of M1 and M2 macrophages toward disease progression remains unclear.Methods: We evaluated macrophage phenotypes histopathologically using skin biopsy samples obtained from patients with CS (n = 8) and SS (n = 31) and performed immunostaining with CD68, iNOS (M1 macrophages), PD‐L1, and CD163 (M2 macrophages).Results: The density of CD163‐positive cells in the SS group was significantly higher than that in the CS group. There was no significant correlation between the CD163 (+) cell density and serum angiotensin‐converting enzyme level, serum calcium, or tuberculin reaction.Conclusions: Immunostaining for CD163 may be a novel and useful marker to predict systemic involvement in patients with cutaneous lesions of epithelioid granulomas.
- 3 March 2020
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 47 (7) , 584-591
CD163‐positive macrophage infiltration predicts systemic involvement in sarcoidosis
Background: Sarcoidosis is a chronic and systemic inflammatory disease, in which patients present with noncaseating epithelioid granulomas. Cutaneous lesions of sarcoidosis develop in 9% to 35% of all sarcoidosis patients and comprise various clinical subtypes. It usually affects multiple organs and has a variable clinical course; this is called systemic sarcoidosis (SS). However, occasionally, it only affects the skin and is then called cutaneous sarcoidosis (CS). Recent observations suggest that serum levels of soluble CD163 correlate with immune cell activity in sarcoidosis patients; however, the contribution of M1 and M2 macrophages toward disease progression remains unclear.Methods: We evaluated macrophage phenotypes histopathologically using skin biopsy samples obtained from patients with CS (n = 8) and SS (n = 31) and performed immunostaining with CD68, iNOS (M1 macrophages), PD‐L1, and CD163 (M2 macrophages).Results: The density of CD163‐positive cells in the SS group was significantly higher than that in the CS group. There was no significant correlation between the CD163 (+) cell density and serum angiotensin‐converting enzyme level, serum calcium, or tuberculin reaction.Conclusions: Immunostaining for CD163 may be a novel and useful marker to predict systemic involvement in patients with cutaneous lesions of epithelioid granulomas.
- 10 January 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (3) , E79-E80
Case of bullous pemphigoid following Hailey–Hailey disease with novel mutation of the ATP2C1 gene
- 10 January 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (3) , E79-E80
Case of bullous pemphigoid following Hailey–Hailey disease with novel mutation of the ATP2C1 gene
- 28 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (2) , 89-103
Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
- 28 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (2) , 89-103
Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019
With consideration of the ongoing developments in treatment options for cutaneous melanoma, the Japanese Skin Cancer Society published the first guidelines for cutaneous melanoma in 2007 and later revised them in 2015. Here, we report on an English version of the 2019 Japanese Melanoma Guidelines. In this latest edition, all processes were carried out according to the Grading of Recommendations, Assessment, Development and Evaluation system. A comprehensive published work search, systematic review and determination of recommendations in each clinical question were performed by a multidisciplinary expert panel consisting of dermatologists, a plastic and reconstructive surgeon, and a radiation oncologist. The advent of novel agents, such as immune checkpoint inhibitors and molecular‐targeted agents, has drastically changed the nature of treatment for adjuvant and advanced‐stage diseases among melanoma patients worldwide. Additionally, recent reports of clinical trials regarding surgical procedures and a better understanding of molecular biology and tumor immunology in clinical types of melanoma have had an impact on clinical practise. Based on these viewpoints, eight relevant clinical questions were raised in this report that aim to help clinicians select the appropriate therapeutic approach.
- Open Access
- 1 January 2019
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 28 (1) , 15-18
A case of pseudohypoparathyroidism type Ia with a novel frameshift mutation in the GNAS gene: early diagnosis of osteoma cutis by skin biopsy
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2019
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 28 (1) , 15-18
Open AccessA case of pseudohypoparathyroidism type Ia with a novel frameshift mutation in the GNAS gene: early diagnosis of osteoma cutis by skin biopsy
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2019
- Published by Elsevier in Journal of Dermatological Science
- Vol. 93 (1) , 41-49
Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis
- 1 January 2019
- Published by Elsevier in Journal of Dermatological Science
- Vol. 93 (1) , 41-49
Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis
- 23 September 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 60 (2) , 143-144
Subcutaneous nodules at progesterone injection sites after fertility treatment
- 23 September 2018
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 60 (2) , 143-144
Subcutaneous nodules at progesterone injection sites after fertility treatment
- 1 May 2018
- Published by JLE in European Journal Of Dermatology
- Vol. 28 (3) , 419-421
Juvenile-onset psoriatic arthritis: a survey by the Japanese Society for Psoriasis Research
- 1 May 2018
- Published by JLE in European Journal Of Dermatology
- Vol. 28 (3) , 419-421
Juvenile-onset psoriatic arthritis: a survey by the Japanese Society for Psoriasis Research
- Open Access
- 13 November 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (11) , 2402
Clinical Usefulness of the Platelet-to Lymphocyte Ratio in Patients with Angiosarcoma of the Face and Scalp
Angiosarcoma of the face and scalp (ASFS) is an extremely aggressive tumor that frequently metastasizes, often leading to death. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are inflammatory markers that predict outcome of various cancers. We aimed to examine the relationship between pretreatment inflammatory markers and ASFS outcome. We included 17 patients with ASFS and a control group of 56 age- and gender-matched healthy individuals. Total white blood counts, neutrophil, lymphocyte, monocyte, and platelet counts were recorded; NLR, PLR, and LMR were calculated. Kaplan–Meier curves were used to calculate overall survival (OS) and distant metastasis-free survival (DMFS). Optimal cut-off values for each inflammatory marker were calculated using receiver operating curve analysis. Median follow-up was 22 months (range, 6–75). There was a statistically significant difference in absolute neutrophil counts and NLR between patient and control groups. Two-year OS and DMFS rates were 41% and 35%, respectively. In patients with tumors < 10 cm, PLR was highly correlated with DMFS, with the 2-year DMFS for those with a high PLR being 50% compared with 100% for those with a low PLR (p = 0.06). This study suggests that PLR is superior to NLR and LMR, and is a clinically useful marker in patients with ASFS with small tumors.
- 13 November 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (11) , 2402
Open AccessClinical Usefulness of the Platelet-to Lymphocyte Ratio in Patients with Angiosarcoma of the Face and Scalp
Angiosarcoma of the face and scalp (ASFS) is an extremely aggressive tumor that frequently metastasizes, often leading to death. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are inflammatory markers that predict outcome of various cancers. We aimed to examine the relationship between pretreatment inflammatory markers and ASFS outcome. We included 17 patients with ASFS and a control group of 56 age- and gender-matched healthy individuals. Total white blood counts, neutrophil, lymphocyte, monocyte, and platelet counts were recorded; NLR, PLR, and LMR were calculated. Kaplan–Meier curves were used to calculate overall survival (OS) and distant metastasis-free survival (DMFS). Optimal cut-off values for each inflammatory marker were calculated using receiver operating curve analysis. Median follow-up was 22 months (range, 6–75). There was a statistically significant difference in absolute neutrophil counts and NLR between patient and control groups. Two-year OS and DMFS rates were 41% and 35%, respectively. In patients with tumors < 10 cm, PLR was highly correlated with DMFS, with the 2-year DMFS for those with a high PLR being 50% compared with 100% for those with a low PLR (p = 0.06). This study suggests that PLR is superior to NLR and LMR, and is a clinically useful marker in patients with ASFS with small tumors.
- 1 September 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (12) , e346-e347
Squamous cell carcinoma of neck metastasized to the lung and cervical lymph nodes, successfully treated with systemic docetaxel and local radiation therapy to the neck in a renal transplant patient
- 1 September 2017
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (12) , e346-e347
Squamous cell carcinoma of neck metastasized to the lung and cervical lymph nodes, successfully treated with systemic docetaxel and local radiation therapy to the neck in a renal transplant patient